Regenerative Therapy

Cartilage Repair – Tissue Implant

New Therapy Expert — Tue, 15 May 2012 14:33:21 +0000

Regenerative medicine company Histogenics Corporation, announced today the presentation of intermediate term data supporting the clinical efficacy of the Company’s NeoCart Autologous Cartilage Tissue Implant (ACTI) for periods of up to five years with no evidence of severe treatment-related adverse events in patients with grade III chondral injury to the femur (cartilage damage in the knee).
NeoCart® is an implant grown ex vivo (outside the body) from the patient’s own cartilage cells.
NeoCart recently entered a Phase 3 clinical trial.

Histogenics company website:
http://www.histogenics.com/ MA USA.

Embryonic versus adult stem cells

New Therapy Expert — Thu, 10 May 2012 08:53:14 +0000

Embryonic versus adult stem cells – Illustrated explanations

http://www.youtube.com/watch?v=3Axkn8G18t8&feature=related

Cancer Immunotherapy

New Therapy Expert — Sat, 28 Apr 2012 15:51:06 +0000

Tumor Immunology and Immunotherapy

Nature Reviews Issue dedicated entierly to the subject.

http://www.nature.com/reviews/focus/tumourimmunology/index.html

Disc Repair Phase 2 Trial Update

New Therapy Expert — Wed, 18 Apr 2012 15:55:37 +0000

Report on intermediate results of clinical study:

The publication showed that a single non-surgical injection of Mesoblast’s allogeneic mesenchymal progenitor cells (MPCs) into damaged intervertebral discs resulted in significant regeneration of disc anatomy, increase in proteoglycan content, and increase in disc height, for at least six months.

Published in:

Journal of Neurosurgery, Posted online on March 9, 2012

Entitled “Immunoselected STRO-3+mesenchymal precursor cells and restoration of the extracellular matrix of degenerate intervertebral discs”, can be viewed at:

http://thejns.org/doi/full/10.3171/2012.1.SPINE11852

Mesoblast, Australia

Limb Ischemia treatment with mesenchymal stem cells

New Therapy Expert — Tue, 10 Apr 2012 06:19:30 +0000

Paper title:

“Cellular Therapy With Ixmyelocel-T to Treat Critical Limb Ischemia: The Randomized, Double-blind, Placebo-controlled RESTORE-CLI Trial”

Richard J Powell et al. Molecular Therapy ( April 2012)

From the abstract:

“Ixmyelocel-T is a patient-specific, expanded, multicellular therapy evaluated in patients with lower extremity critical limb ischemia (CLI) with no options for revascularization. This randomized, double-blind, placebo-controlled, phase 2 trial (RESTORE-CLI) compared the efficacy and safety of intramuscular injections of ixmyelocel-T with placebo.

“ Ixmyelocel-T treatment was well tolerated and may offer a potential new treatment option.”

http://www.nature.com/mt/journal/vaop/ncurrent/abs/mt201252a.html?elq=acdd72b49f7c46d29415a48d24ca2aba

Sposored by: Aastrom Biosciences Inc., Ann Arbor, Michigan, USA

Immunotherapy of Melanoma

New Therapy Expert — Mon, 02 Apr 2012 15:10:11 +0000

A new review article on adoptive immunotherapy by Steve Rosenberg:

Sci Transl Med. 2012 Mar 28;4(127):

“Raising the bar: the curative potential of human cancer immunotherapy”.

PubMed: http://www.ncbi.nlm.nih.gov/pubmed/22461638

Abstract

“Immunotherapy with interleukin-2 can cure 5 to 10% of patients with metastatic melanoma and renal cancer. Recent adoptive cell transfer (ACT) immunotherapies have improved cure rates in metastatic melanoma to 20 to 40%. Genetic engineering of T cells to express conventional alpha/beta T cell receptors or antibody-based chimeric antigen receptors provides an opportunity to extend ACT to patients with common epithelial cancers.”

ALS treatment with neural stem cells

New Therapy Expert — Fri, 30 Mar 2012 05:05:58 +0000

Title:

Lumbar Intraspinal Injection of Neural Stem Cells in Patients with ALS: Results of a Phase I Trial in 12 Patients.

Glass JD, et al Stem Cells. 2012 Mar 13. [Epub ahead of print]

Abstract:

http://www.ncbi.nlm.nih.gov/pubmed/22415942.1

Phase I safety trial of intraspinal injections of fetal-derived neural stems cells in patients with Amyotrophic Lateral Sclerosis (ALS).

Emory University School of Medicine, Atlanta, GA USA

Breast reconstruction surgery by stem cells

New Therapy Expert — Tue, 20 Mar 2012 09:42:58 +0000

CYTORI BREAST RECONSTRUCTION CELL THERAPY TRIAL RESULTS PUBLISHED

http://ir.cytori.com/InvestorRelations/releasedetail.cfm?ReleaseID=657974

Published in:

“Prospective trial of Adipose-Derived Regenerative Cell (ADRC)-enriched fat grafting for partial mastectomy defects: The RESTORE-2 trial”

R. Pérez-Canoa, J.J. Vranckxb, J.M. Lassoa, C. Calabresec, B. Merckd, A.M. Milsteine, E. Sassoonf, E. Delayg, E.M. Weiler-Mithoffh,

European Journal of Surgical Oncology – March 2012

Ischemic stroke treatment with stem cells

New Therapy Expert — Tue, 20 Mar 2012 06:15:46 +0000

A phase I/II clinical study using modified non related stem cells for treating stable ischemic stroke.

Recruiting patients April 2011

http://clinicaltrials.gov/ct2/show/NCT01287936?term=Stanford%2C+SanBio&rank=1

Performed in Stanford University School of Medicine, CA US.

Sponsored by SanBio Inc. http://www.san-bio.com/

March 2012

SanBio Announces Enrollment of First Cohort of Patients in Its Clinical Trial of Stem Cell Therapy for Chronic Stroke

http://www.san-bio.com/news/documents/SanBio_First_Cohort_2012.03.20.pdf

Kidney transplant facilitated by stem cells

New Therapy Expert — Mon, 12 Mar 2012 11:02:36 +0000

Abstract:

Title: “Chimerism and Tolerance Without GVHD or Engraftment Syndrome in HLA-Mismatched Combined Kidney and Hematopoietic Stem Cell Transplantation.”

Induction of immune tolerence by organ donor hematopoietic stem cells enables kidney transplant following immune suppression.

“These results suggest that manipulation of a mobilized stem cell graft and nonmyeloablative conditioning represents a safe, practical, and reproducible means of inducing durable chimerism and donor-specific tolerance in solid organ transplant recipients.”

Leventhal J, Abecassis M, Miller J, Gallon L, Ravindra K, Tollerud DJ, King B, Elliott MJ, Herzig G, Herzig R, Ildstad ST.

Sci Transl Med. 2012 Mar 7;4(124)

Source – PubMed: http://www.ncbi.nlm.nih.gov/pubmed/22399264